Breaking News
Start for Free 0
👀 Ones to watch: Undervalued stocks to buy before they report Q3 earnings See Undervalued Stocks
Close

Elevance Health (E1LV34)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
566.72 +17.54    +3.19%
01:28:59 - Closed. Currency in BRL ( Disclaimer )
Type:  Equity
Market:  Brazil
ISIN:  BRE1LVBDR002 
  • Volume: 56
  • Bid/Ask: 566.16 / 569.52
  • Day's Range: 561.68 - 566.72
Elevance 566.72 +17.54 +3.19%

BVMF:E1LV34 Financials

 
Gain a comprehensive overview of Elevance financials. Assess key figures from the balance sheet and income statement. Explore essential metrics such as total assets, total liabilities, equity, revenue, and net income to understand the company’s overall financial performance.

Elevance Health, Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported revenue was USD 43,886 million compared to USD 43,672 million a year ago. Net income was USD 2,300 million compared to USD 1,853 million a year ago. Diluted earnings per share from continuing operations was USD 9.85 compared to USD 7.79 a year ago.For the six months, revenue was USD 86,463 million compared to USD 85,844 million a year ago. Net income was USD 4,546 million compared to USD 3,842 million a year ago. Diluted earnings per share from continuing operations was USD 19.44 compared to USD 16.1 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

E1LV34 Income Statement

Gross margin TTM 28.34%
Operating margin TTM 6.14%
Net Profit margin TTM 3.9%
Return on Investment TTM 11.85%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 43646 42577 42647 42849
Gross Profit 13074 12031 11313 12243
Operating Income 3026 3204 2404 2643
Net Income 2300 2246 856 1289

E1LV34 Balance Sheet

Quick Ratio MRQ 1.05
Current Ratio MRQ 1.49
LT Debt to Equity MRQ 58.21%
Total Debt to Equity MRQ 72.02%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 112988 111894 108928 110478
Total Liabilities 70691 71184 69523 71939
Total Equity 42297 40710 39405 38539

E1LV34 Cash Flow Statement

Cash Flow/Share TTM 8.89
Revenue/Share TTM 738.84
Operating Cash Flow  1.07%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 447 1978 -2971 2613
Cash From Investing Activities -818 -2310 -1029 -687
Cash From Financing Activities 668 32 -394 -994
Net Change in Cash 271 -300 -4393 928
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

E1LV34 Comments

Write your thoughts about Elevance Health
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email